1-cyclohexyl-3-[3-(1H-imidazol-1-yl)propyl]thiourea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-cyclohexyl-3-[3-(1H-imidazol-1-yl)propyl]thiourea
• 英文别名: 1-cyclohexyl-3-(3-imidazol-1-ylpropyl)thiourea
• 化学式: C₁₃H₂₂N₄S
• 分子量: 266.41
• InChiKey: WIIHBWBHMLCVSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  74
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(3-氨基丙基)咪唑 、 环己基异硫氰酸脂 以 乙醇 为溶剂， 反应 3.0h， 以43%的产率得到1-cyclohexyl-3-[3-(1H-imidazol-1-yl)propyl]thiourea
  参考文献：
  名称：

  有效的非硫脲H3受体组胺拮抗剂的设计。

  摘要：

  从第一个有效的选择性H3受体组胺拮抗剂thioperamide开始，已经合成了类似物，并在大鼠大脑皮质进行了体外测试，以探索其结构活性之间的关系。目的是设计不具有硫代过酰胺的硫脲基团并且可以改善脑渗透性的有效化合物。在短系列的开链硫脲类似物中，发现H3拮抗剂效能的最佳链长为（CH2）3。衍生自组胺并在侧链氨基上具有芳族含氮杂环而不是硫脲的化合物具有H3拮抗活性。此外，当杂环为2-吡啶基时，吡啶5-位上的吸电子取代基（例如NO 2，CF 3，CO 2 Me）增加了效力。描述了4- [4（5）-咪唑基]哌啶的合成及其向硫代过酰胺的（三氟甲基）吡啶基类似物5b的转化。然而，5b不如硫代过酰胺强。用吡啶取代咪唑或在远处的N上取代咪唑会大大降低效力。用S取代侧链NH进一步提高了效力，最有效的化合物是2-（[2- [4（5）-咪唑基]乙基]硫基] -5-硝基吡啶（UCL 1199），其Ki = 4.8

  DOI：

  10.1021/jm00017a018

文献信息

• New use of glutaminyl cyclase inhibitors
  申请人：Probiodrug AG

  公开号：EP2481408A2

  公开（公告）日：2012-08-01

  The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis, b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas, e. metabolic diseases, e.g. hypertension, f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis. Further, the invention relates to a respective diagnostic method, assay and kit.

  本发明总体上涉及谷氨酰胺肽环转酶的抑制剂，以及将其用于治疗和/或预防选 自以下一组炎症性疾病的疾病或紊乱 a. 神经退行性疾病，例如轻度认知障碍（MCI）、阿尔茨海默病、唐氏综合征的神经退行性疾病、家族性英国痴呆症、家族性丹麦痴呆症、多发性硬化症、 b. 慢性和急性炎症，如类风湿性关节炎、动脉粥样硬化、血管再狭窄、胰腺炎、 c. 纤维化，如肺纤维化、肝纤维化、肾纤维化、 d. 癌症，如癌症/血管内皮瘤增生、胃癌、 e. 代谢性疾病，如高血压、 f. 其他炎症性疾病，如神经性疼痛、移植物排斥/移植物失败/移植物血管病变、艾滋病病毒感染/艾滋病、妊娠中毒症、结节性硬化症。 此外，本发明还涉及一种相应的诊断方法、检测方法和试剂盒。
• The First Potent Inhibitors for Human Glutaminyl Cyclase:  Synthesis and Structure−Activity Relationship
  作者：Mirko Buchholz、Ulrich Heiser、Stephan Schilling、André J. Niestroj、Katrin Zunkel、Hans-Ulrich Demuth

  DOI：10.1021/jm050756e

  日期：2006.1.1

  The first effective inhibitors for human glutaminyl cyclase (QC) are described. The structures are developed by applying a ligand-based optimization approach starting from imidazole. Screening of derivatives of that heterocycle led to compounds of the imidazol-1-yl-alkyl thiourea type as a lead scaffold. A library of thiourea derivatives was synthesized, resulting in an inhibitory improvement by 2 orders of magnitude, leading to 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea as a potent inhibitor. Systematic exploitation of the scaffold revealed a strong impact on the inhibitory efficacy and resulted in the development of imidazole-propyl-thioamides as another new class of potent inhibitors. A flexible alignment of the most potent compounds of the thioamide and thiourea class and a QC substrate revealed a good match of characteristic features of the molecules, which suggests a similar binding mode of both inhibitors and the substrate to the active site of QC.
• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Probiodrug AG

  公开号：EP1713780B1

  公开（公告）日：2012-01-18
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Schilling Stephan

  公开号：US20090018087A1

  公开（公告）日：2009-01-15

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
• USE OF GLUTAMINYL CYCLASE INHIBITORS
  申请人：Schilling Stephan

  公开号：US20090068699A1

  公开（公告）日：2009-03-12

  An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis, b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas, e. metabolic diseases, e.g. hypertension, f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis. Additionally disclosed are a respective diagnostic method, assay and kit.